Skip to main content
Top
Published in: Diabetes Therapy 3/2024

Open Access 30-01-2024 | Type 1 Diabetes | Original Research

Association Between Adherence, A1C Improvement, and Type of Continuous Glucose Monitoring System in People with Type 1 Diabetes or Type 2 Diabetes Treated with Intensive Insulin Therapy

Authors: Poorva M. Nemlekar, Katia L. Hannah, Courtney R. Green, Gregory J. Norman

Published in: Diabetes Therapy | Issue 3/2024

Login to get access

Abstract

Introduction

Use of continuous glucose monitoring (CGM) systems by people with diabetes is associated with improved glycemic outcomes, including lower glycated hemoglobin (A1C). Less is known about adherence to CGM systems, whether glycemic outcomes are impacted by levels of adherence, or whether adherence rates differ between types of CGM systems—intermittently scanned CGM (isCGM) or real-time CGM (rtCGM).

Methods

A retrospective analysis of de-identified US administrative health claims and linked laboratory data was conducted using the Merative™ MarketScan® Research Database. The cohort included CGM-naïve people with type 1 diabetes (T1D) or type 2 diabetes treated with intensive insulin therapy (T2D-IIT) who initiated rtCGM or isCGM between August 1, 2019 and March 31, 2021 (defined as the index date). Adherence was calculated over a 12-month period using the proportion of days covered (PDC) with PDC ≥ 0.8 defined as adherent. A1C values were obtained within 6 months of the index date.

Results

A total of 7669 individuals were identified. Subgroups included T1D using isCGM (n = 1578), T1D using rtCGM (n = 1244), T2D-IIT using isCGM (n = 3567), and T2D-IIT using rtCGM (n = 1280). After 12 months, PDC was 0.71 (0.30)–0.72 (0.31) (mean(SD)) for T1D and T2D-IIT rtCGM users and 0.55 (0.34)–0.56 (0.34) for T1D and T2D-IIT isCGM users. The proportion of adherent users (PDC ≥ 0.8) was 56.8–59.7% for rtCGM users and 36.3–37.6% for isCGM users. Overall, regardless of diabetes type, the odds of adherence were over two times higher for rtCGM users compared to isCGM users. For those with available A1C information (T1D n = 213; T2D-IIT n = 346), independent of CGM type, adherence to CGM was associated with a greater reduction in A1C and more people reaching A1C targets of < 7.0% or < 8.0%.

Conclusion

For people with T1D or T2D-IIT, higher adherence to CGM is associated with greater reductions in A1C, and higher adherence rates were observed with rtCGM systems than with isCGM systems.
Literature
6.
15.
go back to reference Johnson LM, Swarner SL, van der Straten A, Rothrock GD. In: Methods for assessing the adherence to medical devices. Research Triangle Park: RTI; 2016. Johnson LM, Swarner SL, van der Straten A, Rothrock GD. In: Methods for assessing the adherence to medical devices. Research Triangle Park: RTI; 2016.
16.
go back to reference Reaven PD, Newell M, Rivas S, Zhou X, Norman GJ, Zhou JJ. Initiation of continuous glucose monitoring is linked to improved glycemic control and fewer clinical events in type 1 and type 2 diabetes in the Veterans Health Administration. Diabetes Care. 2023;46(4):854–63. https://doi.org/10.2337/dc22-2189.CrossRefPubMed Reaven PD, Newell M, Rivas S, Zhou X, Norman GJ, Zhou JJ. Initiation of continuous glucose monitoring is linked to improved glycemic control and fewer clinical events in type 1 and type 2 diabetes in the Veterans Health Administration. Diabetes Care. 2023;46(4):854–63. https://​doi.​org/​10.​2337/​dc22-2189.CrossRefPubMed
18.
go back to reference Charleer S, De Block C, Bolsens N, et al. Sustained impact of intermittently scanned continuous glucose monitoring on treatment satisfaction and severe hypoglycemia in adults with type 1 diabetes (FUTURE): an analysis in people with normal and impaired awareness of hypoglycemia. Diabetes Technol Ther. 2023;25(4):231–41. https://doi.org/10.1089/dia.2022.0452.CrossRefPubMed Charleer S, De Block C, Bolsens N, et al. Sustained impact of intermittently scanned continuous glucose monitoring on treatment satisfaction and severe hypoglycemia in adults with type 1 diabetes (FUTURE): an analysis in people with normal and impaired awareness of hypoglycemia. Diabetes Technol Ther. 2023;25(4):231–41. https://​doi.​org/​10.​1089/​dia.​2022.​0452.CrossRefPubMed
20.
go back to reference DCCT/EDIC Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45(10):1289–98.CrossRef DCCT/EDIC Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45(10):1289–98.CrossRef
21.
go back to reference Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care. 2016;39(5):686–93. https://doi.org/10.2337/dc15-1990.CrossRef Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care. 2016;39(5):686–93. https://​doi.​org/​10.​2337/​dc15-1990.CrossRef
23.
go back to reference Alshannaq H, Norman GJ, Lynch PM. 141-LB: cost-effectiveness of real-time continuous glucose monitoring (rt-CGM) vs. intermittent-scanning continuous glucose monitoring (is-CGM) from a U.S. payer perspective in patients with type 2 diabetes on multiple daily injections of insulin (PwT2D on MDI). Diabetes. 2023. https://doi.org/10.2337/db23-141-LB.CrossRef Alshannaq H, Norman GJ, Lynch PM. 141-LB: cost-effectiveness of real-time continuous glucose monitoring (rt-CGM) vs. intermittent-scanning continuous glucose monitoring (is-CGM) from a U.S. payer perspective in patients with type 2 diabetes on multiple daily injections of insulin (PwT2D on MDI). Diabetes. 2023. https://​doi.​org/​10.​2337/​db23-141-LB.CrossRef
Metadata
Title
Association Between Adherence, A1C Improvement, and Type of Continuous Glucose Monitoring System in People with Type 1 Diabetes or Type 2 Diabetes Treated with Intensive Insulin Therapy
Authors
Poorva M. Nemlekar
Katia L. Hannah
Courtney R. Green
Gregory J. Norman
Publication date
30-01-2024
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 3/2024
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-023-01529-8

Other articles of this Issue 3/2024

Diabetes Therapy 3/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.